Table 1.
Four-fold table of disproportionality methods.
Table 2.
Formulas and threshold values of ROR and PRR.
Fig 1.
The flowchart of identifying cilostazol related adverse events in FAERS database.
Note: DEMO, demographic and administrative information; DRUG, drug information; REAC, adverse event coding; ROR, reporting odds ratio.
Fig 2.
Proportion of adverse drug outcomes.
Note: DE, death; DS, disability; HO, hospitalization; LT, life-threatening; OT, other; RI, required intervention to prevent permanent impairment.
Table 3.
Clinical characteristics of reports with cilostazol.
Fig 3.
Note: JP, Japan; US, The United States; KR, Korea; DE, Germany; ES, Spain; PH, Philippines; UK, The United Kingdom; CN, China.
Fig 4.
Distribution of adverse events due to cilostazol reported annually.
Table 4.
The positive signal strength and the frequency of reports in the top 30 PT of cilostazol.
Table 5.
Signal strength of reports of cilostazol at the SOC level in FAERS database.
Fig 5.
Positive risk signals for cardiovascular adverse events with cilostazol.
Fig 6.
PT distribution of cardiovascular adverse events with cilostazol.
Table 6.
Time-to-onset analysis for signals with cilostazol.
Fig 7.
Time-to-onset of cilostazol related adverse events.